Oral contraceptives and skin cancer: Is there a link?

American Journal of Clinical Dermatology

Volumn 6, Issue 6, 2005, Pages 349-355

  Leslie, Kimberly K ^a   Espey, Eve ^a  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT; TAMOXIFEN;

BREAST CANCER; CANCER GENETICS; CANCER RISK; CLINICAL TRIAL; GENOMICS; HORMONE ACTION; HUMAN; HYPERPIGMENTATION; MELANOMA; ORAL CONTRACEPTION; PRIORITY JOURNAL; REVIEW; SKIN; SKIN CANCER; SKIN CARCINOGENESIS; STATISTICAL SIGNIFICANCE;

ANIMALS; CELL CYCLE; CONTRACEPTIVES, ORAL, HORMONAL; GONADAL STEROID HORMONES; HUMANS; MELANOMA; RECEPTORS, STEROID; SKIN; SKIN NEOPLASMS;

EID: 31144479671     PISSN: 11750561     EISSN: 11750561     Source Type: Journal    
DOI: 10.2165/00128071-200506060-00002     Document Type: Review

References (65)

1. Jensen EV, DeSombre ER. Estrogen-receptor interaction. Science 1973; 182 (108): 126-34
2. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988; 240 (4854): 889-95
3. Onate SA, Tsai SY, Tsai MJ, et al. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995; 270 (5240): 1354-7
4. Carroll JS, Swarbrick A, Musgrove EA, et al. Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens. Cancer Res 2002; 62 (11): 3126-31
5. Webb P, Nguyen P, Valentine C, et al. The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol Endocrinol 1999; 13 (10): 1672-85
6. Kushner PJ, Agard DA, Greene GL, et al. Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 2000; 74 (5): 311-7
7. Kushner PJ, Agard D, Feng WJ, et al. Oestrogen receptor function at classical and alternative response elements. Novartis Found Symp 2000; 230: 20-6
8. Horwitz KB, Alexander PS. In situ photolinked nuclear progesterone receptors of human breast cancer cells: subunit molecular weights after transformation and translocation. Endocrinology 1983; 113 (6): 2195-201
9. Lessey BA, Alexander PS, Horwitz KB. The subunit structure of human breast cancer progesterone receptors: characterization by chromatography and photoaffinity labeling. Endocrinology 1983; 112 (4): 1267-74
10. Arnett-Mansfield RL, deFazio A, Wain GV, et al. Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res 2001; 61 (11): 4576-82
11. Hanekamp EE, Kuhne EC, Smid-Koopman E, et al. Loss of progesterone receptor may lead to an invasive phenotype in human endometrial cancer. Eur J Cancer 2002; 38 Suppl. 6: S71-2
12. Gregory CW, He B, Wilson EM. The putative androgen receptor-A form results from in vitro proteolysis. J Mol Endocrinol 2001; 27 (3): 309-19
13. Tilley WD, Marcelli M, Wilson JD, et al. Characterization and expression of a cDNA encoding the human androgen receptor. Proc Natl Acad Sci U S A 1989; 86 (1): 327-31
14. Wilson CM, McPhaul MJ. A and B forms of the androgen receptor are present in human genital skin fibroblasts. Proc Natl Acad Sci U S A 1994; 91 (4): 1234-8
15. Catalano MG, Pfeffer U, Raineri M, et al. Altered expression of androgen-receptor isoforms in human colon-cancer tissues. Int J Cancer 2000; 86 (3): 325-30
16. Ho KJ, Liao JK. Nonnuclear actions of estrogen. Arterioscler Thromb Vasc Biol 2002; 22 (12): 1952-61
17. McCann JP, Mayes JS, Hendricks GR, et al. Subcellular distribution and glycosylation pattern of androgen receptor from sheep omental adipose tissue. J Endocrinol 2001; 169 (3): 587-93
18. Harvey BJ, Doolan CM, Condliffe SB, et al. Non-genomic convergent and divergent signaling of rapid responses to aldosterone and estradiol in mammalian colon. Steroids 2002; 67 (6): 483-91
19. Singleton DW, Feng Y, Burd CJ, et al. Nongenomic activity and subsequent c-fos induction by estrogen receptor ligands are not sufficient to promote deoxyribonucleic acid synthesis in human endometrial adenocarcinoma cells. Endocrinology 2003; 144 (1): 121-8
20. Filardo EJ. Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer. J Steroid Biochem Mol Biol 2002; 80 (2): 231-8
21. Filardo EJ, Quinn JA, Frackelton AR, et al. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol 2002; 16 (1): 70-84
22. Ahola TM, Alkio N, Manninen T, et al. Progestin and G protein-coupled receptor 30 inhibit mitogen-activated protein kinase activity in MCF-7 breast cancer cells. Endocrinology 2002; 143 (12): 4620-6
23. Ahola TM, Manninen T, Alkio N, et al. G protein-coupled receptor 30 is critical for a progestin-induced growth inhibition in MCF-7 breast cancer cells. Endocrinology 2002; 143 (9): 3376-84
24. Ahola TM, Purmonen S, Pennanen P, et al. Progestin upregulates G-protein-coupled receptor 30 in breast cancer cells. Eur J Biochem 2002; 269 (10): 2485-90
25. Fraser D, Padwick ML, Whitehead M, et al. Presence of an oestradiol receptor-related protein in the skin: changes during the normal menstrual cycle. Br J Obstet Gynaecol 1991; 98 (12): 1277-82
26. Pelletier G, El-Alfy M. Immunocytochemical localization of estrogen receptors alpha and beta in the human reproductive organs. J Clin Endocrinol Metab 2000; 85 (12): 4835-40
27. Sun J, Baudry J, Katzenellenbogen JA, et al. Molecular basis for the subtype discrimination of the estrogen receptor-beta-selective ligand, diarylpropionitrile. Mol Endocrinol 2003; 17 (2): 247-58
28. Sun J, Huang YR, Harrington WR, et al. Antagonists selective for estrogen receptor alpha. Endocrinology 2002; 143 (3): 941-7
29. Shiau AK, Barstad D, Radek JT, et al. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat Struct Biol 2002; 9 (5): 359-64
30. Harris HA, Katzenellenbogen JA, Katzenellenbogen BS. Characterization of the biological roles of the estrogen receptors, ERα and ERβ, in estrogen target tissues in vivo through the use of an ERα-selective ligand. Endocrinology 2002; 143 (11): 4172-7
31. Rickard DJ, Waters KM, Ruesink TJ, et al. Estrogen receptor isoform-specific induction of progesterone receptors in human osteoblasts. J Bone Miner Res 2002; 17 (4): 580-92
32. Lindberg MK, Moverare S, Skrtic S, et al. Estrogen receptor (ER)-β reduces ERα-regulated gene transcription, supporting a 'ying yang' relationship between ERα and ERβ in mice. Mol Endocrinol 2003; 17 (2): 203-8
33. Moverare S, Lindberg MK, Faergemann J, et al. Estrogen receptor-α, but not estrogen receptor-β, is involved in the regulation of the hair follicle cycling as well as the thickness of epidermis in male mice. J Invest Dermatol 2002; 119 (5): 1053-8
34. Avila DM, Wilson CM, Nandi N, et al. Immunoreactive AR and genetic alterations in subjects with androgen resistance and undetectable AR levels in genital skin fibroblast ligand-binding assays. J Clin Endocrinol Metab 2002; 87 (1): 182-8
35. Alesci S, Bornstein SR. Neuroimmunoregulation of androgens in the adrenal gland and the skin. Horm Res 2000; 54 (5-6): 281-6
36. Labrie F, Luu-The V, Labrie C, et al. Intracrinology and the skin. Horm Res 2000; 54 (5-6): 218-29
37. Nelson LR, Bulun SE. Estrogen production and action. J Am Acad Dermatol 2001; 45 (3 Suppl.): S116-24
38. Izu K, Yamamoto O, Yamaguchi J, et al. A case of autoimmune progesterone dermatitis [in German]. J Uoeh 2001; 23 (4): 431-6
39. Uotinen N, Puustinen R, Pasanen S, et al. Distribution of progesterone receptor in female mouse tissues. Gen Comp Endocrinol 1999; 115 (3): 429-41
40. Kommoss F, Kiechle-Schwarz M, Dubois A, et al. Co-cultivation of ovarian carcinoma cells with dermal fibroblasts induces fibroblast expression of sex steroid receptor transcripts and protein. Int J Gynecol Cancer 1995; 5 (2): 101-6
41. Im S, Lee ES, Kim W, et al. Expression of progesterone receptor in human keratinocytes. J Korean Med Sci 2000; 15 (6): 647-54
42. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288 (3): 321-33
43. Brekelmans CT. Risk factors and risk reduction of breast and ovarian cancer. Curr Opin Obstet Gynecol 2003; 15 (1): 63-8
44. Matsumura Y, Ananthaswamy HN. Molecular mechanisms of photocarcinogenesis. Front Biosci 2002; 7: d765-83
45. Nataraj AJ, Trent JC, Ananthaswamy HN. p53 gene mutations and photocarcinogenesis. Photochem Photobiol 1995; 62 (2): 218-30
46. Nishigori C, Yarosh DB, Donawho C, et al. The immune system in ultraviolet carcinogenesis. J Investig Dermatol Symp Proc 1996; 1 (2): 143-6
47. van Steeg H, Kraemer KH. Xeroderma pigmentosum and the role of UV-induced DNA damage in skin cancer. Mol Med Today 1999; 5 (2): 86-94
48. McGregor JM, Yu CC, Dublin EA, et al. Aberrant expression of p53 tumour-suppressor protein in non-melanoma skin cancer. Br J Dermatol 1992; 127 (5): 463-9
49. Shea CR, McNutt NS, Volkenandt M, et al. Overexpression of p53 protein in basal cell carcinomas of human skin. Am J Pathol 1992; 141 (1): 25-9
50. Stephenson TJ, Royds J, Silcocks PB, et al. Mutant p53 oncogene expression in keratoacanthoma and squamous cell carcinoma. Br J Dermatol 1992; 127 (6): 566-70
51. Kimonis VE, Goldstein AM, Pastakia B, et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet 1997; 69 (3): 299-308
52. Pierceall WE, Goldberg LH, Tainsky MA, et al. Ras gene mutation and amplification in human nonmelanoma skin cancers. Mol Carcinog 1991; 4 (3): 196-202
53. Pierceall WE, Mukhopadhyay T, Goldberg LH, et al. Mutations in the p53 tumor suppressor gene in human cutaneous squamous cell carcinomas. Mol Carcinog 1991; 4 (6): 445-9
54. Dai D, Litman ES, Schonteich E, et al. Progesterone regulation of activating protein-1 transcriptional activity: a possible mechanism of progesterone inhibition of endometrial cancer cell growth. J Steroid Biochem Mol Biol 2003; 87 (2-3): 123-31
55. Dai D, Wolf DM, Litman ES, et al. Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors. Cancer Res 2002; 62 (3): 881-6
56. Rogers GS, Flowers JL, Pollack SV, et al. Determination of sex steroid receptor in human basal cell carcinoma. J Am Acad Dermatol 1988; 18 (5 Pt 1): 1039-43
57. Gefeller O, Hassan K, Wille L. Cutaneous malignant melanoma in women and the role of oral contraceptives. Br J Dermatol 1998; 138 (1): 122-4
58. Miller JG, Gee J, Price A, et al. Investigation of oestrogen receptors, sex steroids and soluble adhesion molecules in the progression of malignant melanoma. Melanoma Res 1997; 7 (3): 197-208
59. Ladanyi A, Timar J, Bocsi J, et al. Sex-dependent liver metastasis of human melanoma lines in SCID mice. Melanoma Res 1995; 5 (2): 83-6
60. Kanda N, Watanabe S. 17beta-estradiol, progesterone, and dihydrotestosterone suppress the growth of human melanoma by inhibiting interleukin-8 production. J Invest Dermatol 2001; 117 (2): 274-83
61. Richardson B, Price A, Wagner M, et al. Investigation of female survival benefit in metastatic melanoma. Br J Cancer 1999; 80 (12): 2025-33
62. Beral V, Ramcharan S, Faris R. Malignant melanoma and oral contraceptive use among women in California. Br J Cancer 1977; 36 (6): 804-9
63. Pfahlberg A, Hassan K, Wille L, et al. Systematic review of case-control studies: oral contraceptives show no effect on melanoma risk. Public Health Rev 1997; 25 (3-4): 309-15
64. Karagas MR, Stukel TA, Dykes J, et al. A pooled analysis of 10 case-control studies of melanoma and oral contraceptive use. Br J Cancer 2002; 86 (7): 1085-92
65. Feskanich D, Hunter DJ, Willett WC, et al. Oral contraceptive use and risk of melanoma in premenopausal women. Br J Cancer 1999; 81 (5): 918-23